Anti-Coagulants - Zambia

  • Zambia
  • The Anti-Coagulants market in Zambia is projected to generate a revenue of US$4.49m in 2024.
  • It is expected to experience an annual growth rate (CAGR 2024-2029) of 8.40%, leading to a market volume of US$6.72m by 2029.
  • When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to US$16,740.00m in 2024.
  • Zambia's anti-coagulant market is witnessing a surge in demand due to the increasing prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Anti-Coagulants market in Zambia has been showing significant growth in recent years.

Customer preferences:
Zambian customers are increasingly looking for effective and affordable treatment options for blood clotting disorders. There is a growing demand for anti-coagulants due to the rising prevalence of conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE) in the country. Patients are also becoming more aware of the benefits of early detection and treatment of these conditions, which is driving the demand for anti-coagulants.

Trends in the market:
One of the key trends in the Zambian anti-coagulants market is the increasing availability of generic drugs. This has led to a reduction in the cost of treatment, making it more accessible to a larger section of the population. There is also a trend towards the use of direct oral anti-coagulants (DOACs) over traditional warfarin therapy. DOACs offer several advantages over warfarin, including fewer drug interactions and the absence of the need for regular blood monitoring.

Local special circumstances:
The Zambian healthcare system faces several challenges, including a shortage of healthcare professionals and limited access to medical facilities in rural areas. This has led to a focus on developing primary healthcare services and improving access to essential medicines across the country. The government has also introduced several initiatives to increase the availability of anti-coagulants, including the inclusion of these drugs in the Essential Medicines List (EML) and the introduction of public-private partnerships to improve the distribution of medicines.

Underlying macroeconomic factors:
Zambia has a growing economy, with a focus on developing the healthcare sector. The government has increased healthcare spending in recent years, which has led to improvements in the availability and quality of healthcare services across the country. The government's focus on expanding access to essential medicines is also driving the growth of the anti-coagulants market in Zambia. Additionally, the country's growing population and rising life expectancy are contributing to the increase in demand for anti-coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)